“A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis”, J of Skin, vol. 5, no. 6, p. s94, Nov. 2021, doi: 10.25251/skin.5.supp.94.